Sharon A. Riddler

6.7k total citations · 1 hit paper
95 papers, 4.4k citations indexed

About

Sharon A. Riddler is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Sharon A. Riddler has authored 95 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Virology, 64 papers in Infectious Diseases and 29 papers in Emergency Medicine. Recurrent topics in Sharon A. Riddler's work include HIV Research and Treatment (67 papers), HIV/AIDS Research and Interventions (50 papers) and HIV/AIDS drug development and treatment (45 papers). Sharon A. Riddler is often cited by papers focused on HIV Research and Treatment (67 papers), HIV/AIDS Research and Interventions (50 papers) and HIV/AIDS drug development and treatment (45 papers). Sharon A. Riddler collaborates with scholars based in United States, South Africa and Uganda. Sharon A. Riddler's co-authors include John W. Mellors, Charles R. Rinaldo, Joseph B. Margolick, Roger Detels, Richard Haubrich, John Phair, Karin L. Klingman, Lawrence Kingsley, William G. Powderly and Kevin W. Garren and has published in prestigious journals such as New England Journal of Medicine, JAMA and The Journal of Immunology.

In The Last Decade

Sharon A. Riddler

88 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

2008 500 citations Sharon A. Riddler, Richard Haubrich et al. profile →

Peers

Countries citing papers authored by Sharon A. Riddler

Since Specialization

Citations

This map shows the geographic impact of Sharon A. Riddler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon A. Riddler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon A. Riddler more than expected).

Fields of papers citing papers by Sharon A. Riddler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon A. Riddler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon A. Riddler. The network helps show where Sharon A. Riddler may publish in the future.

Co-authorship network of co-authors of Sharon A. Riddler

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon A. Riddler. A scholar is included among the top collaborators of Sharon A. Riddler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon A. Riddler. Sharon A. Riddler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action 2024 ·Journal of Chromatography B ·Raymond E. West, (unknown), (unknown), Sharon A. Riddler, Thomas D. Nolin, (unknown)	0
2	A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention 2024 ·The Journal of Infectious Diseases ·Sharon A. Riddler, Clifton W. Kelly, Craig Hoesley, Ken Ho, Jeanna Piper, (unknown), (unknown), Gustavo F. Doncel, Sherri Johnson, Peter L. Anderson, Rhonda M. Brand, Ratiya Pamela Kunjara Na Ayudhya, José A. Bauermeister, Sharon L. Hillier, Craig W. Hendrix	1
3	A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod 2024 ·Infectious Diseases and Therapy ·Sharon A. Riddler, Constance A. Benson, (unknown), Steven G. Deeks, Edwin DeJesus, (unknown), Michael F. Para, Moti Ramgopal, Yanhui Cai, (unknown), (unknown), Wendy Jiang, Xiaopeng Liu, (unknown), (unknown), Christiaan R. de Vries, Jeffrey J. Wallin, Elena Vendrame, Devi SenGupta	1
4	Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015 2024 ·UNC Libraries ·Vanessa Elharrar, Sharon A. Riddler, Edward Livant, Arendevi Pather, Francis Martinson, (unknown), Jennifer E. Balkus, Marla Husnik, Urvi M. Parikh, (unknown), Pamina M. Gorbach, Margaret P. Kasaro, Lisa Levy, Bonus Makanani	0
5	Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring 2018 ·Clinical Infectious Diseases ·Sharon A. Riddler, Jennifer E. Balkus, Urvi M. Parikh, John W. Mellors, Carolyne A. Akello, Sufia Dadabhai, Felix Mhlanga, Gita Ramjee, Ashley Mayo, Edward Livant, Amy Heaps, Colin O’Rourke, Jared M. Baeten, (unknown)	11
6	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation 2017 ·PLoS Pathogens ·Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Christina M. Lalama, Joshua C. Cyktor, Bernard Macatangay, Charles R. Rinaldo, Sharon A. Riddler, Evelyn Hogg, Catherine Godfrey, Ann C. Collier, Joseph J. Eron, John W. Mellors, (unknown)	130
7	Efavirenz decreases etonogestrel exposure 2017 ·AIDS ·Catherine A. Chappell, Mohammed Lamorde, (unknown), Beatrice A. Chen, (unknown), Sharon A. Riddler, Susan E. Cohn, Kristin M. Darin, Sharon L. Achilles, Kimberly K. Scarsi	31
8	Efavirenz — but not nevirapine — based antiretroviral therapy significantly reduces etonogestrel concentrations among HIV-positive women using subdermal contraceptive implants 2016 ·Contraception ·Catherine A. Chappell, Mohammed Lamorde, (unknown), (unknown), Sharon A. Riddler, Sylvia Cohn, Kristin M. Darin, Sharon L. Achilles, Kimberly K. Scarsi	1
9	Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015 2016 ·HIV Clinical Trials ·Sharon A. Riddler, Marla Husnik, Pamina M. Gorbach, Lisa Levy, Urvi M. Parikh, Edward Livant, Arendevi Pather, Bonus Makanani, (unknown), Margaret P. Kasaro, Francis Martinson, Vanessa Elharrar, Jennifer E. Balkus, (unknown)	5
10	Long-term Follow-up of HIV Seroconverters from the VOICE Trial - An Analysis of Data from MTN-015 2014 ·AIDS Research and Human Retroviruses ·Sharon A. Riddler, Marla Husnik, Arendevi Pather, Thesla Palanee‐Phillips, Gonasagrie Nair, Felix Mhlanga, Marthinette Taljaard, Clemensia Nakabiito, (unknown), Lisa Levy, Vanessa Elharrar, Gita Ramjee, Jennifer E. Balkus, (unknown)	0
11	HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy 2014 ·Clinical Infectious Diseases ·Guillaume Besson, Christina M. Lalama, Ronald J. Bosch, Rajesh T. Gandhi, Margaret A Bedison, Evgenia Aga, Sharon A. Riddler, Deborah K. McMahon, Feiyu Hong, John W. Mellors	164
12	Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jessica H. Brehm, Christina M. Lalama, Michael D. Hughes, Richard Haubrich, Sharon A. Riddler, Nicolas Sluis‐Cremer, John W. Mellors	3
13	Delaying a Treatment Switch in Antiretroviral-Treated HIV Type 1-Infected Patients with Detectable Drug-Resistant Viremia Does Not Have a Profound Effect on Immune Parameters: AIDS Clinical Trials Group Study A5115 2009 ·AIDS Research and Human Retroviruses ·Allan R. Tenorio, Hongyu Jiang, Yu Zheng, Barbara Bastow, Daniel R. Kuritzkes, John Bartlett, Steven G. Deeks, Alan Landay, Sharon A. Riddler	2
14	Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. 2005 ·PubMed ·Xiuhong Li, Joseph B. Margolick, Craig Conover, Sheila Badri, Sharon A. Riddler, Mallory D. Witt, Lisa P. Jacobson	102
15	Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003 2005 ·AIDS ·Eric C. Seaberg, Álvaro Muñoz, Ming‐Chi Lu, Roger Detels, Joseph B. Margolick, Sharon A. Riddler, Carolyn Williams, John Phair	253
16	Short Communication: Suction-Assisted Lipectomy for Lipodystrophy 2004 ·AIDS Research and Human Retroviruses ·(unknown), Ernest K. Manders, Sharon A. Riddler	12
17	Anthropometrics and Examiner‐Reported Body Habitus Abnormalities in the Multicenter AIDS Cohort Study 2004 ·Clinical Infectious Diseases ·Frank J. Palella, Stephen R. Cole, Joan S. Chmiel, Sharon A. Riddler, Barbara R. Visscher, Adrian S. Dobs, Carolyn Williams	46
18	Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men 2003 ·AIDS ·Bryan Lau, Stephen J. Gange, John Phair, Sharon A. Riddler, Roger Detels, Joseph B. Margolick	19
19	Thrush and Fever as Markers of Immune Competence in the Era of Highly Active Antiretroviral Therapy 2001 ·AIDS Research and Human Retroviruses ·Richard L. Skolasky, John J. Phair, Roger Detels, Sharon A. Riddler, Joseph B. Margolick, Lisa P. Jacobson	10
20	Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T) 1995 ·Antiviral Research ·Sharon A. Riddler, Robert E. Anderson, John W. Mellors	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact